Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes

International Journal of Cancer

Volumn 111, Issue 4, 2004, Pages 617-626

  Tanaka, Tomotaka ^a   Tanimoto, Keiji ^a   Otani, Keiko ^a   Satoh, Kenichi ^a   Otaki, Megu ^a   Yoshida, Kazuhiro ^a   Toge, Tetsuya ^a   Yahata, Hiroshi ^b   Tanaka, Shinji ^b   Chayama, Kazuaki ^c   Okazaki, Yasushi ^d   Hayashizaki, Yoshihide ^d   Hiyama, Keiko ^a   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

CDNA microarray; Chemosensitivity prediction; Drug action determinant; Gene expression; Personalized medicine

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; COMPLEMENTARY DNA; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOMYCIN C; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ABCB1 GENE; ABCG2 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYP2C8 GENE; CYP3A4 GENE; CYTOTOXICITY; DNA MICROARRAY; DPYD GENE; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GSTP1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MARKER GENE; MGMT GENE; MODEL; NQO1 GENE; POR GENE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL TIME; TOP2A GENE; TREATMENT FAILURE; TUBB GENE; TUMOR GROWTH; TYMS GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; FLUOROURACIL; FORECASTING; GENE EXPRESSION PROFILING; HUMANS; MODELS, THEORETICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 3843082080     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20289     Document Type: Article

References (34)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
2. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000;2:article 4.
3. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000;61:199-203.
4. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;23:236-44.
5. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3:75-82.
6. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochem Biophys Acta 2003;1603:99-111.
7. Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit Rev Oncol Hematol 2003;46:59-100.
8. Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 2001;62:1311-36.
9. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98:10787-92.
10. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.
11. Koizumi W, Kurihara M, Nakano S, Hasegawa K. For the S-1 Cooperative Gastric Cancer Study Group. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
12. Sakakura C, Hagiwara A, Nakanishi M, Shimomura K, Takagi T, Yasuoka R, Fujita Y, Abe T, Ichikakwa Y, Takahashi S, Ishikawa T, Nishizuka I, et al. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer 2002;87:1153-61.
13. Morita T, Togo S, Kubota T, Kamimukai N, Nishizuka I, Kobayashi T, Ichikawa Y, Ishikawa T, Takahashi S, Matsuo K, Tomaru Y, Okazaki Y, et al. Mechanism of postoperative liver failure after excessive hepatectomy investigated using a cDNA microarray. J Hepatobiliary Pancreat Surg 2002;9:352-9.
14. Rousseeuw PJ. Least median of squares regression. J Am Statist Assoc 1984;79:871-80.
15. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999;5:2672-3.
16. Zhang K, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998;12:871-82.
17. Nishiyama M, Suzuki K, Kumazaki T, Yamamoto W, Toge T, Okamura T, Kurisu K. Molecular targeting of mitomycin C chemotherapy, Int J Cancer 1997;72:649-56.
18. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27:251-5.
19. 6-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 2002;93:93-102.
20. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
21. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;30:438-45.
22. Ringel I, Horwitz SB. Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
23. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28:27-47.
24. Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Differential toxicity of mytomycin C and porifiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci USA 1996;93:456-60.
25. Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 2003;42:237-43.
26. Mathijssen RHJ, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
27. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human cancer cell lines. Cancer Res 1990;50:7962-5.
28. Okamoto R, Takano H, Sekikawa T, Tanaka T, Toyoda M, Ukon K, Tanimoto K, Kumazaki T, Nishiyama M. Unique action determinants of double acting topoisomerase inhibitor, TAS-103. Int J Oncol 2001;19:921-7.
29. Sawamura AO, Aoyama T, Tamakoshi K, Mizuno K, Suganuma N, Kikkawa F, Tomoda Y. Transfection of human cytochrome P-450 reductase cDNA and its effect on the sensitivity to toxins. Oncology 1996;53:406-11.
30. Park JS, Yamamoto W, Sekikawa T, Matsukawa M, Okamoto R, Sasaki M, Ukon K, Tanimoto K, Kumazaki T, Nishiyama M. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 2002;20:333-8.
31. Akaike H. Information theory and an extension of the maximum principle. In: Proceedings of the 2nd International Symposium on Information Theory. Budapest: Akademia Kiado, 1973. 267-81.
32. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001;61:6474-9.
33. Kuo MT, Bao JJ, Curley SA, Ikeguchi M, Johnston DA, Ishikawa T. Frequent coordinated overexpression of the MRP/GS-X pump and γ-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 1996;56:3642-4.
34. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001;61:4689-92.